Topiramate and Metformin Are Effective Add-On Treatments in Controlling Antipsychotic-Induced Weight Gain: A Systematic Review and Network Meta-Analysis-Reference-Cited by-同舟云学术

Topiramate and Metformin Are Effective Add-On Treatments in Controlling Antipsychotic-Induced Weight Gain: A Systematic Review and Network Meta-Analysis

Published:2018-11-28 Issue: Volume:9 Page:
ISSN:1663-9812
Container-title:Frontiers in Pharmacology
language:
Short-container-title:Front. Pharmacol.

Author:

Zhuo Chuanjun,Xu Yong,Liu Sha,Li Jing,Zheng Qishi,Gao Xiangyang,Li Shen,Jing Rixing,Song Xueqin,Yue Weihua,Zhou Chunhua,Upthegrove Rachel

Publisher

Frontiers Media SA

Subject

Pharmacology (medical),Pharmacology

Reference69 articles.

1. Topiramate add-on treatment in schizophrenia: a randomized, double-blind, placebo-controlled clinical trial.;Afshar;J. Psychopharmacol.,2009

2. Non-pharmacological management of antipsychotic-induced weight gain: systematic review and meta-analysis of randomized controlled trials.;Alvarez-Jimenez;Br. J. Psychiatry,2008

3. Metformin for treatment of overweight induced by atypical antipsychotic medication in young people with autism spectrum disorder: a randomized clinical trial.;Anagnostou;JAMA Psychiatry,2016

4. Add-on combination and maintenance treatment: case series of five obese patients with different eating behavior.;Anghelescu;J. Clin. Psychopharmacol.,2002

5. A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents.;Arman;Saudi Med. J.,2008

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of topiramate in reducing second‐generation antipsychotic‐associated weight gain among children: A systematic review and meta‐analysis;Diabetes, Obesity and Metabolism;2024-03-13

2. Glucagon-like peptide-1 receptor-agonists treatment for cardio-metabolic parameters in schizophrenia patients: a systematic review and meta-analysis;Frontiers in Psychiatry;2023-05-05

3. Second to none: rationale, timing, and clinical management of clozapine use in schizophrenia;Therapeutic Advances in Psychopharmacology;2023-01

4. Stress, psychiatric disease, and obesity: An Obesity Medicine Association (OMA) Clinical Practice Statement (CPS) 2022;Obesity Pillars;2022-12

5. Treating Obesity in Children and Adolescents with Special Healthcare Needs;Current Obesity Reports;2022-11-02